Akèy › Leksemi mieloïd egi › Alabama › Birmingham
Etid klinik pou Leksemi mieloïd egi nan Birmingham, AL
21 etid pou Leksemi mieloïd egi ap chèche patisipan nan sit nan ak bò kote Birmingham (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Ap rekriteFaz 2
- University of Alabama at Birmingham Cancer Center, Birmingham
A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
Ap rekriteFaz 1
- Children's Hospital of Alabama, Birmingham
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- University of Alabama at Birmingham Cancer Center, Birmingham
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Ap rekriteFaz 3
- University of Alabama at Birmingham, Birmingham
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- University of Alabama at Birmingham Cancer Center, Birmingham
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- University of Alabama at Birmingham Cancer Center, Birmingham
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Ap rekriteFaz 3
- Children's Hospital of Alabama, Birmingham
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
Ap rekriteFaz 2
- University of Alabama - Birmingham, Birmingham
Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
Ap rekriteFaz 3
- Children's Hospital of Alabama, Birmingham
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Ap rekriteFaz 1/2
- O'Neal Comprehensive Cancer Center, University of Alabama, Birmingham
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Ap rekriteFaz 1/2
- Children's Hospital of Alabama, Birmingham
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
Ap rekriteFaz 2/3
- University of Alabama Birmingham, Birmingham
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Ap rekriteEtid obsèvasyon
- University of Alabama at Birmingham, Birmingham
A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers
Ap rekrite
- University of Alabama at Birmingham, Division of Hematology and Oncology, Birmingham
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Ap rekriteFaz 2
- University of Alabama Birmingham, Birmingham
Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies
Ap rekriteFaz 1
- University of Alabama at Birmingham, Birmingham
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Ap rekriteFaz 1
- University of Alabama O'Neal Cancer Center, Birmingham
HPC Offered for PRESERVE Expansion
Ap rekriteEtid obsèvasyon
- University of Alabama, Birmingham, Birmingham
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Ap rekriteFaz 1/2
- The Kirklin Clinic of UAB Hospital, Birmingham
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
Ap rekriteVolontè an sante akeyi
- University of Alabama - Birmingham, Birmingham
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
Ap rekriteFaz 1
- University of Alabama at Birmingham, Birmingham
Etid Leksemi mieloïd egi nan lòt vil
- Houston, TX85 etid
- New York City, NY51 etid
- Boston, MA44 etid
- Seattle, WA41 etid
- Baldwin Park, CA40 etid
- Columbus, OH35 etid
- Philadelphia, PA34 etid
- Durham, NC33 etid
- Atlanta, GA31 etid
- Tampa, FL29 etid
- Chicago, IL26 etid
- Portland, OR25 etid
Lòt etid nan Birmingham
- Kansè (tout kalite)31 etid
- Kansè nan tete24 etid
- Kansè ovè23 etid
- Obèsite23 etid
- Kansè Poumon ki pa ti selil22 etid
- Myelom Miltip18 etid
- BPCO17 etid
- Maladi kadyovaskilè17 etid
- Dyabèt Tip 216 etid
- Kansè Endomèt16 etid
- Sipwa16 etid
- Fibroz sistik16 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.